CA-TAULIA
21.11.2023 09:01:31 CET | Business Wire | Press release
Taulia, a leading provider of working capital management solutions, has partnered with Mastercard to launch Taulia Virtual Cards. The new solution provides businesses with additional working capital management advantages, including the ability to maximize cash flow and minimize payment uncertainty. Following Taulia Virtual Cards’ seamless integration across SAP ERP solutions, including SAP S/4HANA and other major enterprise resource planning (ERP) platforms, corporates can streamline previously cumbersome payment-related tasks more effectively and affordably.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231121680451/en/
Initially, two major banks - Degussa Bank and HSBC - are set to participate. Taulia customers will benefit through their existing issuer relationships, meaning customers can deploy virtual cards and extend the current benefits offered by their own banks through Taulia, while also enjoying the speed, controls, and efficiency of virtual card payments. This “bring your own bank” capability is made possible by Taulia’s integration with Mastercard’s innovative virtual card platform, which is connected with more than 80 banks globally.
This partnership will allow Taulia to expand its working capital solutions for businesses by leveraging virtual cards generated through Mastercard upon request, providing significant time and cost savings to corporates seeking more consumer-grade user experiences in their enterprise platforms.
Through the tightly integrated virtual card experience, businesses benefit from greater spend control and more options to pay suppliers efficiently. On the other end, suppliers gain improved cash flow and enhanced visibility, alleviating friction across B2B transactions.
Danielle Weinblatt, Chief Product Officer, Taulia, commented: “We are delighted to be partnering with Mastercard, doubling down on our commitment to transform the world of global trade and commerce by bringing our customers a fully embedded working capital management solution that prioritizes the customer experience.”
Rebecca Meeker, Senior Vice President, Global Partnerships and Segments, Mastercard, commented: “Fragmented B2B payment practices have held businesses back for too long. Virtual cards accelerate automation and support cash flow through increased access to working capital, which is why Mastercard is thrilled to work with Taulia and its banking partners to extend the benefits of virtual cards while prioritizing customer experience.”
Arati Kurien, Global Head of Commercial Cards Product Management, HSBC, commented: “We’re pleased to be embracing innovation through our partnerships with Taulia and Mastercard, which will now provide our clients with an integrated virtual card payment solution within the Taulia platform. Embedding HSBC’s financial services into the systems that our clients use day to day is a key focus for us.”
Matthias Weiß, Board Member, Degussa Bank AG, commented: “We are very excited to provide our customers an SAP-integrated virtual credit card solution and are looking forward to a successful partnership with Taulia to grow our German procurement footprint.”
ENDS
About Taulia
Taulia is a fintech provider of working capital management solutions headquartered in San Francisco, California. Taulia helps companies access value tied up in their payables, receivables, and inventory. Taulia's platform and network of more than 3 million businesses enables customers to execute their working capital strategies, support their suppliers with early payment, and contribute to building sustainable supply chains. Taulia processes more than $500 billion each year and is trusted by the world’s largest companies, including Airbus, AstraZeneca, and Nissan. In March 2022, Taulia became part of SAP. For more information, please visit www.taulia.com.
About Degussa Bank
Degussa Bank AG is a retail bank based in Frankfurt/Main, Germany. It offers a wide range of financial services to employees of partner companies (B2C) as well as to corporates (B2B). Degussa Bank is a leading B2B Commercial card issuer in Germany and Austria. Degussa Bank card solution rely on customer centric solutions with a high standard of data management with several integration opportunities to T&E, Accounting- and ERP-Systems. Degussa Bank has over 20 years’ experience in card issuing and over 10 years especially with virtual cards.
About HSBC
HSBC Holdings plc, is a public limited company incorporated in England. Headquartered in London, HSBC is listed on the London, Hong Kong, New York, and Bermuda stock exchanges. The entities that form the HSBC Group provide a comprehensive range of financial services. Our international network comprises some 3,500+ offices in 62 countries and territories in Europe, the Asia-Pacific region, the Americas, the Middle East, and Africa. We serve over 39 million customers through three global businesses: Wealth and Personal Banking (‘WPB'), Commercial Banking ('CMB'), and Global Banking and Markets ('GBM'). HSBC offers a wide range of services to all sizes of business, from multinationals to small and medium-sized enterprises. Services include traditional corporate banking facilities, such as bank accounts, money transmission services, overdrafts, short and medium-term loans, treasury and foreign exchange, trade services, and global cash management, including corporate cards.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231121680451/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom